Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thiol and amine groups in skin proteins and biomolecules serve as the primary nucleophilic targets for electrophilic chemicals, a process central to the development of skin sensitization (OECD, 2012). These functional groups are predominantly found on cysteine and lysine residues within abundant skin proteins such as keratin and human serum albumin (Gerberick et al., 2007). The covalent modification of these groups by haptens—small, reactive molecules—forms immunogenic hapten-protein complexes, which is the first key event in the Adverse Outcome Pathway (AOP) for allergic contact dermatitis (Aptula et al., 2005). While these groups are not therapeutic targets in the conventional sense, their reactivity is a critical parameter in the safety evaluation of topical pharmaceuticals and cosmetic ingredients (Karlberg et al., 2008). Understanding the kinetics and specificity of these interactions is essential for predicting the allergenic potential of new chemical entities using in chemico methods like the Direct Peptide Reactivity Assay (DPRA) (Natsch et al., 2013). These interactions can lead to the activation of the innate immune system and the subsequent priming of T-cells, resulting in a delayed-type hypersensitivity reaction upon re-exposure. Monitoring the depletion of synthetic peptides containing these groups is a standard regulatory approach for assessing skin sensitization risk. Beyond toxicology, these groups are also involved in the structural integrity of the skin barrier through the formation of disulfide bonds in the cornified envelope.
Covalent binding (haptenization) to nucleophilic sites on skin proteins, leading to the formation of complete antigens and subsequent T-cell mediated immune responses.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thiol and amine groups in skin proteins and biomolecules (None).